Study to Evaluate Safety and Dosimetry of Lutathera in Adolescent Patients With GEP-NETs and PPGLs
A phase 2 trial of Lutetium-177 dotatate in pheochromocytoma and paraganglioma, run by Advanced Accelerator Applications, active and no longer recruiting.
Overview
Study to Evaluate Safety and Dosimetry of Lutathera in Adolescent Patients With GEP-NETs and PPGLs is a phase 2 interventional study registered as NCT04711135 by Advanced Accelerator Applications, with 11 participants enrolled, started 2022-08-31 and due to reach its primary completion in 2024-03-12. Interventions recorded: Lutetium [177Lu] oxodotreotide/dotatate. Conditions listed: Gastroenteropancreatic Neuroendocrine Tumors, Pheochromocytoma, Paraganglioma. No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialA Study of [177Lu]Lu-DOTA-TATE in Newly Diagnosed ES-SCLC Patients in Combination With Carboplatin, Etoposide and Atezolizumab
Shares Novartis, Lutetium-177 dotatate, Lutetium-177.
- IdeaBuild Western ytterbium-176 enrichment so lutetium-177 has more than one supplier
Shares Novartis, Lutetium-177 dotatate, Lutetium-177.
- TrialStudy of Lutetium (177Lu) Vipivotide Tetraxetan in mCRPC Participants With Moderately and Severely Impaired and With Normal Renal Function
Shares Novartis, Lutetium-177.
- TrialOpen-label Study Comparing AAA817 Versus Standard of Care in the Treatment of Previously Treated PSMA-positive mCRPC Adults Who Have Disease Progressed on or After [177Lu]Lu-PSMA Targeted Therapy
Shares Novartis, Lutetium-177.
- TrialAn Open-label Study Comparing Lutetium (177Lu) Vipivotide Tetraxetan Versus Observation in PSMA Positive OMPC.
Shares Novartis, Lutetium-177.
- TrialAn Open-label Study of Lutetium (177Lu) Vipivotide Tetraxetan (AAA617) in Combination With ARPI Versus AAA617 in PSMA Positive First-line mCRPC
Shares Novartis, Lutetium-177.
- TrialA Phase Ib/II Open-label Study of AMO959 With Lutetium (177Lu) Vipivotide Tetraxetan (AAA617) in Combination With ARPI in Adult Participants With PSMA
Shares Novartis, Lutetium-177.
- PersonSimron Singh
Shares Lutetium-177 dotatate, Lutetium-177.